0 (0%)		10-31 11:24
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	5.43	1-year :	6.34
Resists	First :	4.65	Second :	5.43
Pivot price	3.59
Supports	First :	3.48	Second :	2.75
MAs	MA(5) :	3.78	MA(20) :	3.75
	MA(100) :	2.17	MA(250) :	1.98
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	47.6	D(3) :	46
RSI	RSI(14): 56.2
52-week	High :	4.84	Low :	0.97

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ZURA ] has closed below upper band by 35.3%. Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.82 - 3.83	3.83 - 3.85
Low:	3.64 - 3.66	3.66 - 3.67
Close:	3.72 - 3.75	3.75 - 3.78

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Fri, 31 Oct 2025
Is ZURA forming a reversal pattern - Insider Selling & High Yield Stock Recommendations - newser.com

Fri, 31 Oct 2025
Comparing ZURA in custom built stock radars - 2025 Top Gainers & Smart Investment Allocation Tips - newser.com

Fri, 31 Oct 2025
Is ZURA stock a smart buy before Fed meeting - Portfolio Profit Report & High Yield Equity Trading Tips - newser.com

Fri, 31 Oct 2025
Is ZURA showing signs of accumulation - Portfolio Performance Summary & Stepwise Trade Execution Plans - newser.com

Fri, 31 Oct 2025
Is ZURA stock attractive for long term wealth building - Watch List & Free Verified High Yield Trade Plans - newser.com

Fri, 31 Oct 2025
Comparing ZURA in custom built stock radars - Earnings Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange:
Sector: Healthcare
Industry: Biotechnology
Shares Out	65 (M)
Shares Float	38 (M)
Held by Insiders	27.7 (%)
Held by Institutions	51.2 (%)
Shares Short	2,620 (K)
Shares Short P.Month	458 (K)

EPS	-0.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.02
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-26.1 %
Return on Equity (ttm)	-43.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.12
Qtrly Earnings Growth	0 %
Operating Cash Flow	-44 (M)
Levered Free Cash Flow	-24 (M)

PE Ratio	-5.03
PEG Ratio	0
Price to Book value	1.83
Price to Sales	0
Price to Cash Flow	-5.56

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.